Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
Shionogi’s single-dose influenza drug Xofluza (baloxavir marboxil) will be added to Japan’s NHI price list on March 14 as a key reimbursement policy panel has given the nod for accelerated listing of what will be the first medicine designated for…
To read the full story
Related Article
- Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
- Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
March 8, 2018
- Shionogi’s Single-Dose Flu Med Gets Accelerated OK
February 26, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
- Shionogi Links Arms with Roche on Sakigake-Designated Anti-Flu Drug
March 1, 2016
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…